In The Lancet Infectious Diseases, Ravindra Gupta and colleagues1 present alarming results on the development of pre-treatment viral resistance to the most commonly used drugs to treat HIV infection in resource-limited countries.
There’s no health without a health workforce: reflections on the ‘Health Heroes +Social Good’ summit
Assessing TB infection control practices in Malawi: research application and implications for the regional response
Tuberculosis (TB) is the 9th leading cause of death worldwide.1 While TB mortality and incidence are decreasing, there are still significant gaps in detection and treatment.2 One in four new TB cases occurred in Africa in 2016, and co-infection with HIV is a notab
The Challenge of a Changing HIV Epidemic
We have come a long way in our response to the HIV epidemic since its beginning. Many critical steps have been made. In the last seven years, new HIV infection rates have dropped almost 30 percent worldwide.
Why Finding New HIV Targets Takes So Long: Some Basics About Basic Research
Although great strides have been made at combating human immunodeficiency virus, leading to better quality of life and a longer life expectancy for those living with the
New Findings Presented at IAS 2017 Reveal More about the Inter-relationship Between the Microbiome and HIV
Over the past several years, research has uncovered just how important the microbiome is to human health.
Making the case for asking key populations about violence: A success story from South Sudan
Before joining the LINKAGES project, I spent most of my career developing, managing, and evaluating gender-based violence (GBV) prevention and response programs for women and girls in emergency, post-conflict, and development settings, as well as in the U.S.
How to effectively and meaningfully engage communities in differentiated service delivery
There is a clear appreciation for the pivotal role that communities have played in the HIV response over the last 32 years, but it’s no surprise that critical gaps remain – particularly with respect to the ways communities are effectively and meaningfully engaged in their care and treatment.
Long-Acting Injectable Antiretrovirals for PrEP: Will the tail wag the drug?
Mark Mascolini is a medical journalist who writes about HIV news, research and global policies for the International AIDS Society and many publications. Emily Bass is the Director of Strategy & Content at AVAC.
